MDM2 and acute myeloid leukemia: Further research into whether the combination of an MDM2 inhibitor and a hypomethylating agent may suppress p53 mutant clones by activating other tumor suppressors (eg, p73) is warranted; studies have suggested that downregulation of p53 in AML cells may result in a functional switch to p73.36